Načítá se...
Thrombin Mutant W215A/E217A Treatment Improves Neurological Outcome and Reduces Cerebral Infarct Size in a Mouse Model of Ischemic Stroke
BACKGROUND AND PURPOSE: Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator (tPA) is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C (APC) improves outcomes; however, APC also has bleedi...
Uloženo v:
| Hlavní autoři: | , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3115697/ https://ncbi.nlm.nih.gov/pubmed/21512172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.110.603811 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|